Faron Pharmaceuticals aktie (FARON)

New review published in Immunotherapy highlights the potential for Clever-1 inhibition with bexmarilimab to become the cornerstone of next-generation, multi-indication cancer immunotherapy

Comprehensive review synthesizes clinical learnings from BEXMAB and MATINS trials, detailing the potential of bexmarilimab in overcoming imm...

MFN • Idag 08:00

Faron Expands Bexmarilimab Program in Solid Tumors with a Randomized Phase I/II BEXAR IIT in Metastatic Soft-Tissue Sarcoma

Study conducted in a collaboration between MEDSIR and University Hospital Vall d’Hebron to evaluate bexmarilimab plus standard-of-care doxor...

MFN • I förrgår 08:00

Faron Pharmaceuticals Ltd: PDMR Dealing

MFN • 13 Jan 17:00

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel imm...

MFN • 08 Jan 18:45

Faron announces strategic collaboration with The Institute for Cancer Research to launch BLAZE trial, targeting immunotherapy resistance in cancer

Investigator-initiated trial aims to provide proof-of-concept for bexmarilimab in overcoming acquired resistance to checkpoint inhibitors, a...

MFN • 22 Dec 2025 08:00

Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board

TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling ...

MFN • 17 Dec 2025 15:30

Faron issues second tranche of bonds with an aggregated principal amount of EUR 10 million under its convertible bond arrangement

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON, “Faron” or the “Company”), a clinical-stage biopharmaceutical co...

MFN • 11 Dec 2025 09:30

Faron presents updated BEXMAB data at ASH 2025: Deep and durable responses in HR-MDS with favorable safety profile

Significant efficacy observed in TP53-mutated patients with a 70% complete remission rate in the frontline HR MDS

MFN • 08 Dec 2025 08:00

Faron Pharmaceuticals Ltd: Holding(s) in Company

MFN • 04 Dec 2025 17:00

Faron Pharmaceuticals Ltd: Registration of New Shares

Capitalised terms used in this announcement have the meanings given to them in the announcement made at 9.

MFN • 03 Dec 2025 11:00

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel imm...

MFN • 03 Dec 2025 08:00

Faron Pharmaceuticals Ltd: Grant of Options

TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling ...

MFN • 02 Dec 2025 08:00

Faron Pharmaceuticals Ltd: Appointment of CFO

Faron appoints new CFO to support next phase of growth

MFN • 01 Dec 2025 08:00

Faron’s Financial Calendar for 2026

MFN • 27 Nov 2025 08:00

INSIDE INFORMATION: FARON INTENDS TO ISSUE SECOND TRANCHE OF BONDS WITH AN AGGREGATED PRINCIPAL AMOUNT OF EUR 10 MILLION UNDER ITS CONVERTIBLE BOND ARRANGEMENT

Inside Information: Faron intends to issue second tranche of bonds with an aggregated principal amount of EUR 10 million under its convertib...

MFN • 24 Nov 2025 18:15

Faron announces two bexmarilimab abstracts accepted at ASH 2025, including an oral presentation on treatment efficacy

This acceptance marks the fifth major medical conference this year to feature bexmarilimab in an oral session, reinforcing the drug's unique...

MFN • 04 Nov 2025 08:00

Faron hits key milestone with BEXMAB Phase 2 completion, advances to registrational trial with FDA alignment

Having achieved all primary endpoints and secured FDA alignment, Faron formally concludes enrolment of the BEXMAB Phase 2 trial as Company’s...

MFN • 03 Nov 2025 08:00

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel imm...

MFN • 28 Oct 2025 08:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

MFN • 21 Oct 2025 15:10

Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients

Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treat...

MFN • 20 Oct 2025 08:00

Faron Pharmaceuticals Ltd: Registration of New Shares

Capitalised terms used in this announcement have the meanings given to them in the announcement made at 9.

MFN • 03 Oct 2025 12:00

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel imm...

MFN • 03 Oct 2025 08:00

Faron Pharmaceuticals Ltd: Exercise of Options, Director Dealing and Issue of Equity

Exercise of Options, Director Dealing and Issue of Equity

MFN • 19 Sep 2025 08:00

Correction: FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 2025

Significant clinical and financial milestones achieved in first half of 2025

MFN • 12 Sep 2025 17:25

FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 2025

Significant clinical and financial milestones achieved in first half of 2025

MFN • 27 Aug 2025 08:00

Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results

Faron Pharmaceuticals will publish its half-year financial results for January-June 2025 on Wednesday 27 August 2025

MFN • 19 Aug 2025 08:00

Inside Information: Faron to advance bexmarilimab into a registrational Phase 2/3 study in treatment-naïve (frontline) HR-MDS after positive meeting with the FDA

Inside Information: Accelerated approval pathway confirmed for frontline patients with CR + CReq, and Overall Survival as primary endpoints

MFN • 18 Aug 2025 08:00

Faron Pharmaceuticals Ltd: Holding(s) in Company

MFN • 08 Aug 2025 16:00

Faron announces extension to its key patent family around bexmarilimab and targeting Clever-1 in cancers with a new US patent granted

MFN • 08 Aug 2025 09:30

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel imm...

MFN • 07 Aug 2025 08:00

Inside Information: Faron to present updated BEXMAB data in frontline HR-MDS to FDA; complete remission rate substantially increased to 43%

Inside Information: Complete remission rate in frontline HR-MDS patients rose from 28% to 43% in latest data cut, confirming the deepening o...

MFN • 06 Aug 2025 08:00

FARON ANNOUNCES ACCEPTANCE OF BEXMARILIMAB DATA FOR ORAL PRESENTATION AT ESMO 2025

Presentation to include the first full pharmacokinetic and pharmacodynamic (PK/PD) data from the BEXMAB study; supports bexmarilimab’s advan...

MFN • 30 Jul 2025 08:30

Faron announces acceptance of two studies involving bexmarilimab, one of them as an oral presentation, at the 19th International Congress of Immunology (IUIS) 2025

The oral presentation and poster showcase bexmarilimab’s dual attack on cancer with new mechanistic data from clinical studies

MFN • 09 Jul 2025 08:00

Faron Pharmaceuticals Ltd: Director Dealing

MFN • 02 Jul 2025 12:00

Faron Pharmaceuticals Ltd: Director/PCA Dealing

MFN • 30 Jun 2025 13:00

Faron-supported research in Theranostics identifies secreted Clever-1 (sClever-1) as an independent driver of immune evasion in cancer, deepening the understanding of bexmarilimab’s mode of action

Study details how bexmarilimab treatment reduces circulating sClever-1 in patients with cancer, a key factor in T-cell suppression and PD-1 ...

MFN • 30 Jun 2025 08:00

Faron Pharmaceuticals presents updated Phase II data from BEXMAB Study at EHA 2025

Strong efficacy and survival outcomes with bexmarilimab in high-risk MDS support Phase III advancement

MFN • 12 Jun 2025 08:00

Faron Pharmaceuticals Ltd: Director/PCA Dealing and Donation of Shares to Foundation

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developin...

MFN • 05 Jun 2025 17:00

Faron Pharmaceuticals Ltd: Registration of New Shares

Registration of New Shares

MFN • 03 Jun 2025 13:00

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds

Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds

MFN • 03 Jun 2025 08:00

Faron Pharmaceuticals presents Phase II data from BEXMAB Study at ASCO 2025

Favorable response rates and survival data in high/very high-risk frontline and r/r MDS support advancement to Phase III trial in frontline ...

MFN • 02 Jun 2025 08:00

Faron announces publication of full Phase I BEXMAB study data in Lancet Haematology

Phase I study shows promising clinical activity and tolerability of bexmarilimab plus standard-of-care in high-risk and HMA-refractory MDS p...

MFN • 30 May 2025 08:00

Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company

Issue of Treasury Shares to the Company

MFN • 27 May 2025 18:00

Faron’s Bexmarilimab demonstrates immune-activating and drug-sensitizing potential in myeloid malignancies

New preclinical data published in Scientific Reports confirms CLEVER-1 inhibition by Bexmarilimab increases antigen presentation and overcom...

MFN • 27 May 2025 08:00

Faron announces new data that highlight patient populations with cancer that are most likely to benefit from first-in-class immunotherapy bexmarilimab

New data published in the Journal for ImmunoTherapy of Cancerreveals how tumor microenvironment shapes response to bexmarilimab along with a...

MFN • 23 May 2025 08:00

Faron Appoints Ralph Hughes as Chief Business Officer (CBO)

Ralph Hughes joins Faron to strengthen Commercial Strategy, Business Development and Market Assessment function

MFN • 21 May 2025 08:00

Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at EHA 2025 Congress

Overcoming immune resistance in HR-MDS: Detailed safety and efficacy Phase II data on bexmarilimab to be presented at EHA 2025

MFN • 15 May 2025 08:00

Faron Pharmaceuticals Ltd: Grant of Options

MFN • 14 May 2025 15:00

Faron Pharmaceuticals presents promising Phase 1/2 data from BEXMAB Study at MDS 2025 plenary session

BEXMAB data highlights meaningful clinical benefit, with beneficial immunological and hematological impact in r/r MDS

MFN • 12 May 2025 08:00

Faron announces acceptance of bexmarilimab Phase II data for oral presentation at ASCO 2025

Data from the BEXMAB study marks a significant milestone for next-generation cancer immunotherapies

MFN • 24 Apr 2025 08:00

Holding in Company

MFN • 17 Apr 2025 14:15

Sisäpiiritieto: Faron julkistaa positiivisia II vaiheen tuloksia hoitoresistentin korkeariskin myelodysplastisen syndrooman hoidossa

Sisäpiiritieto: BEXMAB faasi II -tutkimus saavutti ensisijaisen tavoitteensa hoitoresistentin korkean riskin myelodysplastisen syndrooman ho...

MFN • 15 Apr 2025 08:10

Inside Information: Faron Announces Positive Phase II results in higher-risk myelodysplastic syndrome

Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS (r/r HR MDS)

MFN • 15 Apr 2025 08:00

Inside Information: Faron enters into an up to EUR 35 million convertible bond arrangement and issues first tranche of bonds with a principal amount of EUR 15 million

Inside Information: Faron enters into an up to EUR 35 million convertible bond arrangement to repay its secured loan to IPF and strengthen i...

MFN • 03 Apr 2025 08:00

Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at 2025 Annual MDS Foundation Congress

New analysis and biomarker data strengthens understanding of bexmarilimab’s potential

MFN • 27 Mar 2025 08:00

Board Changes

MFN • 21 Mar 2025 14:15

Results of the Annual General Meeting, Change of Directors, Decision of the Board meeting after the AGM

MFN • 21 Mar 2025 12:45

Shareholders’ Nomination Board updates its recommendation on the number of Board members to be elected and the persons proposed to be elected

Shareholders’ Nomination Board updates its recommendation on the number of Board members to be elected and the persons proposed to be electe...

MFN • 20 Mar 2025 08:00

Inside Information: FDA Grants Orphan Drug Designation for Bexmarilimab in MDS

MFN • 03 Mar 2025 13:00

NOTICE OF FARON PHARMACEUTICALS LTD’S ANNUAL GENERAL MEETING

MFN • 28 Feb 2025 13:00

Inside Information: Faron Receives Positive EMA Opinion on Orphan Drug Designation for Bexmarilimab for the treatment of myelodysplastic syndrome (MDS)

Inside Information: Faron Receives Positive EMA Opinion on Orphan Drug Designation for Bexmarilimab for the treatment of myelodysplastic syn...

MFN • 27 Feb 2025 08:30

Faron Pharmaceuticals Ltd’s Annual Report 2024 published

MFN • 27 Feb 2025 08:15

Faron’s Financial Statement Release 1 January to 31 December 2024

MFN • 27 Feb 2025 08:00

Faron Pharmaceuticals will publish its Financial Statement Release 2024 and Annual Report 2024 on Thursday 27 February 2025

MFN • 19 Feb 2025 11:00

Results of the Significantly Oversubscribed Placing

Inside Information: Announcement of the Results of the Significantly Oversubscribed Placing, the Issue Price and registration of Placing Sha...

MFN • 06 Feb 2025 08:00

Proposed Issue and Placing

Inside Information: Proposed Issue and Placing of preliminarily approx.

MFN • 05 Feb 2025 17:30

Final Patient Identified for the BEXMAB Study

Faron Announces Final Patient Identified for the BEXMAB Phase II Study in Myelodysplastic Syndrome

MFN • 31 Jan 2025 08:00

Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024

GlobeNewswire • 16 May 2024 16:01

Faron Confirms Plans for the Coming Months Under New Leadership

GlobeNewswire • 16 Apr 2024 08:00

Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML

GlobeNewswire • 18 Mar 2024 14:00

Faron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimab

GlobeNewswire • 14 Mar 2024 08:00

Faron’s Financial Statement Release January 1 to December 31, 2023

GlobeNewswire • 13 Mar 2024 08:00

Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population

GlobeNewswire • 25 Jan 2024 08:00

Faron Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Faron Pharmaceuticals to Present at the 42nd Annual J.

GlobeNewswire • 03 Jan 2024 08:00

Inside information: Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th American Society of Hematology (ASH) Annual Meeting

Inside information: Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th American Society of Hematology (ASH) A...

GlobeNewswire • 11 Dec 2023 08:00

Faron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicine

GlobeNewswire • 07 Dec 2023 08:00

Insider information: Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS

GlobeNewswire • 06 Nov 2023 08:00

Inside Information: Announcement of the Results of Placing, the Issue Price and registration of Placing Shares with the Trade Register

GlobeNewswire • 27 Oct 2023 08:05

Inside information: Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML and HMA-Refractory MDS Patients

GlobeNewswire • 11 Oct 2023 13:00

Faron to Host Webcast to Discuss New Data From Phase I/II BEXMAB Study of Bexmarilimab and Provide Update on the Development Outlook for Next 6-9 Months

Faron to Host Webcast to Discuss New Data From Phase I/II BEXMAB Study of Bexmarilimab and Provide Update on the Development Outlook for Ne...

GlobeNewswire • 03 Oct 2023 08:00

Faron Pharmaceuticals Announces Board Changes

GlobeNewswire • 22 Sep 2023 17:00

Faron Pharmaceuticals Ltd Results of the Extraordinary General Meeting

GlobeNewswire • 22 Sep 2023 12:33

Faron Pharmaceuticals Ltd. to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire • 06 Sep 2023 08:00

Faron Reports Half-Year Financial Results, January 1 – June 30, 2023

GlobeNewswire • 29 Aug 2023 06:01

Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemia

GlobeNewswire • 29 Aug 2023 06:00

Faron Pharmaceuticals Notice of Half-Year Financial Results

GlobeNewswire • 04 Aug 2023 14:00

Faron to Hold Conference Call to Discuss New Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS

Faron to Hold Conference Call to Discuss New Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML ...

GlobeNewswire • 19 Jul 2023 10:54

Faron Updates Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS BEXMAB Study Update

GlobeNewswire • 19 Jul 2023 09:00

Pressmeddelanden från Faron Pharmaceuticals

New review published in Immunotherapy highlights the potential for Clever-1 inhibition with bexmarilimab to become the cornerstone of next-generation, multi-indication cancer immunotherapy

Faron Expands Bexmarilimab Program in Solid Tumors with a Randomized Phase I/II BEXAR IIT in Metastatic Soft-Tissue Sarcoma

Faron Pharmaceuticals Ltd: PDMR Dealing

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds

Faron announces strategic collaboration with The Institute for Cancer Research to launch BLAZE trial, targeting immunotherapy resistance in cancer

Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board

Faron issues second tranche of bonds with an aggregated principal amount of EUR 10 million under its convertible bond arrangement

Faron presents updated BEXMAB data at ASH 2025: Deep and durable responses in HR-MDS with favorable safety profile

Faron Pharmaceuticals Ltd: Holding(s) in Company

Faron Pharmaceuticals Ltd: Registration of New Shares

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds

Faron Pharmaceuticals Ltd: Grant of Options

Faron Pharmaceuticals Ltd: Appointment of CFO

Faron’s Financial Calendar for 2026

INSIDE INFORMATION: FARON INTENDS TO ISSUE SECOND TRANCHE OF BONDS WITH AN AGGREGATED PRINCIPAL AMOUNT OF EUR 10 MILLION UNDER ITS CONVERTIBLE BOND ARRANGEMENT

Faron announces two bexmarilimab abstracts accepted at ASH 2025, including an oral presentation on treatment efficacy

Faron hits key milestone with BEXMAB Phase 2 completion, advances to registrational trial with FDA alignment

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients

Faron Pharmaceuticals Ltd: Registration of New Shares

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds

Faron Pharmaceuticals Ltd: Exercise of Options, Director Dealing and Issue of Equity

Correction: FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 2025

FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 2025

Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results

Inside Information: Faron to advance bexmarilimab into a registrational Phase 2/3 study in treatment-naïve (frontline) HR-MDS after positive meeting with the FDA

Faron Pharmaceuticals Ltd: Holding(s) in Company

Faron announces extension to its key patent family around bexmarilimab and targeting Clever-1 in cancers with a new US patent granted

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds

Inside Information: Faron to present updated BEXMAB data in frontline HR-MDS to FDA; complete remission rate substantially increased to 43%

FARON ANNOUNCES ACCEPTANCE OF BEXMARILIMAB DATA FOR ORAL PRESENTATION AT ESMO 2025

Faron announces acceptance of two studies involving bexmarilimab, one of them as an oral presentation, at the 19th International Congress of Immunology (IUIS) 2025

Faron Pharmaceuticals Ltd: Director Dealing

Faron Pharmaceuticals Ltd: Director/PCA Dealing

Faron-supported research in Theranostics identifies secreted Clever-1 (sClever-1) as an independent driver of immune evasion in cancer, deepening the understanding of bexmarilimab’s mode of action

Faron Pharmaceuticals presents updated Phase II data from BEXMAB Study at EHA 2025

Faron Pharmaceuticals Ltd: Director/PCA Dealing and Donation of Shares to Foundation

Faron Pharmaceuticals Ltd: Registration of New Shares

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds

Faron Pharmaceuticals presents Phase II data from BEXMAB Study at ASCO 2025

Faron announces publication of full Phase I BEXMAB study data in Lancet Haematology

Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company

Faron’s Bexmarilimab demonstrates immune-activating and drug-sensitizing potential in myeloid malignancies

Faron announces new data that highlight patient populations with cancer that are most likely to benefit from first-in-class immunotherapy bexmarilimab

Faron Appoints Ralph Hughes as Chief Business Officer (CBO)

Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at EHA 2025 Congress

Faron Pharmaceuticals Ltd: Grant of Options

Faron Pharmaceuticals presents promising Phase 1/2 data from BEXMAB Study at MDS 2025 plenary session

Faron announces acceptance of bexmarilimab Phase II data for oral presentation at ASCO 2025

Holding in Company

Sisäpiiritieto: Faron julkistaa positiivisia II vaiheen tuloksia hoitoresistentin korkeariskin myelodysplastisen syndrooman hoidossa

Inside Information: Faron Announces Positive Phase II results in higher-risk myelodysplastic syndrome

Inside Information: Faron enters into an up to EUR 35 million convertible bond arrangement and issues first tranche of bonds with a principal amount of EUR 15 million

Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at 2025 Annual MDS Foundation Congress

Board Changes

Results of the Annual General Meeting, Change of Directors, Decision of the Board meeting after the AGM

Shareholders’ Nomination Board updates its recommendation on the number of Board members to be elected and the persons proposed to be elected

Inside Information: FDA Grants Orphan Drug Designation for Bexmarilimab in MDS

NOTICE OF FARON PHARMACEUTICALS LTD’S ANNUAL GENERAL MEETING

Inside Information: Faron Receives Positive EMA Opinion on Orphan Drug Designation for Bexmarilimab for the treatment of myelodysplastic syndrome (MDS)

Faron Pharmaceuticals Ltd’s Annual Report 2024 published

Faron’s Financial Statement Release 1 January to 31 December 2024

Faron Pharmaceuticals will publish its Financial Statement Release 2024 and Annual Report 2024 on Thursday 27 February 2025

Holding(s) in Company

Change of Broker

Holding(s) in Company

Results of the Significantly Oversubscribed Placing

Proposed Issue and Placing

Final Patient Identified for the BEXMAB Study

Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024

Faron Confirms Plans for the Coming Months Under New Leadership

Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML

Faron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimab

Faron’s Financial Statement Release January 1 to December 31, 2023

Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population

Faron Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Inside information: Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th American Society of Hematology (ASH) Annual Meeting

Faron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicine